文献速递血栓与止血

艾多沙班治疗慢性血栓栓塞性肺动脉高压的长期真实世界疗效与安全性:全国注册研究

Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study.
PubMed 文献 · J Thromb Haemost · 2026-06-18

基于日本CTEPH AC注册研究,纳入408例注册时接受艾多沙班的CTEPH患者,中位随访552天。1、3、5年临床相关出血累积发生率分别为3.2%、4.8%、5.6%,5年大出血2.4%,症状性静脉血栓栓塞症1.5%,提示长期治疗临床稳定且无明确迟发安全信号。

要点

  • 艾多沙班长期治疗CTEPH患者5年临床相关出血累积发生率为5.6%。
  • 5年大出血发生率为2.4%,症状性静脉血栓栓塞症为1.5%。
  • 不同再灌注史、功能分级、剂量及肾功能亚组结局大体一致。

核心结论

  • 长期艾多沙班治疗与CTEPH患者持续的临床稳定相关。
  • 未观察到明确的迟发安全性信号,但外推至日本以外人群需谨慎。

研究设计与样本

  • 多中心前瞻性观察性队列研究(CTEPH AC注册),纳入注册时接受艾多沙班的CTEPH患者408例,中位随访552天。

主要发现

  • 1、3、5年发病和死亡事件累积发生率分别为4.7%、10.0%、14.1%。
  • 1、3、5年临床相关出血累积发生率分别为3.2%、4.8%、5.6%。
  • 5年大出血发生率为2.4%,症状性静脉血栓栓塞症发生率为1.5%。
  • 不同再灌注史、WHO功能分级、艾多沙班剂量及肾功能分层下结局大体一致。

临床怎么用

  • 在CTEPH患者中可考虑长期使用艾多沙班,但需结合日本以外人群的体型、肾功能及合并用药情况谨慎评估。

局限性

  • 外推至日本以外人群需谨慎,尤其是体型、肾功能或合并用药不同的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term real-world outcomes of edoxaban in chronic thromboembolic pulmonary hypertension (CTEPH) remain incompletely characterized despite emerging evidence, including the KABUKI randomized trial. OBJECTIVES: To evaluate long-term effectiveness and safety of edoxaban in patients with CTEPH using a nationwide registry. METHODS: We analyzed the CTEPH AC Registry, a multicenter prospective observational cohort. Patients with CTEPH receiving edoxaban at registration were included. The primary effectiveness endpoint was morbidity and mortality events, a composite of all-cause death, lung transplantation, rescue pulmonary endarterectomy or balloon pulmonary angioplasty, ≥15% decline in 6-minute walk distance with worsening World Health Organization functional class, or symptomatic venous thromboembolism. The primary safety endpoint was clinically relevant bleeding according to International Society on Thrombosis and Haemostasis criteria. RESULTS: Among 408 patients, median follow-up was 552 days. The cumulative incidence of morbidity and mortality events was 4.7%, 10.0%, and 14.1% at 1, 3, and 5 years, respectively. The cumulative incidence of clinically relevant bleeding was 3.2%, 4.8%, and 5.6%, respectively, and major bleeding occurred in 2.4% at 5 years. Symptomatic venous thromboembolism occurred in 1.5% at 5 years. Outcomes were broadly consistent across reperfusion history, World Health Organization functional class, edoxaban dose, and renal function strata. CONCLUSIONS: In this Japanese nationwide registry, long-term edoxaban therapy was associated with sustained clinical stability in patients with CTEPH. No clear late-emerging safety signal was observed, but extrapolation beyond Japan requires caution, particularly in patients with different body size, renal function, or concomitant medication profiles.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hosokawa K, Masaki K, Hirose M, et al. Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study. J Thromb Haemost. 2026. PMID: 42315026. doi:10.1016/j.jtha.2026.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。